_version_ 1785051524665180160
author Algrin, Caroline
Pérol, Louis
Chapiro, Elise
Baseggio, Lucile
Maloum, Karim
Settegrana, Catherine
Lesesve, Jean-François
Siavellis, Justine
Delmer, Alain
Michallet, Anne-Sophie
Ferrant, Emmanuelle
Feugier, Pierre
Tomowiak, Cécile
Brion, Annie
Ghez, David
Fornecker, Luc-Matthieu
Ivanoff, Sarah
Struski, Stéphanie
Sutton, Laurent
Radford-Weiss, Isabelle
Eclache, Virginie
Lefebvre, Christine
Leblond, Véronique
Nguyen-Khac, Florence
Roos-Weil, Damien
author_facet Algrin, Caroline
Pérol, Louis
Chapiro, Elise
Baseggio, Lucile
Maloum, Karim
Settegrana, Catherine
Lesesve, Jean-François
Siavellis, Justine
Delmer, Alain
Michallet, Anne-Sophie
Ferrant, Emmanuelle
Feugier, Pierre
Tomowiak, Cécile
Brion, Annie
Ghez, David
Fornecker, Luc-Matthieu
Ivanoff, Sarah
Struski, Stéphanie
Sutton, Laurent
Radford-Weiss, Isabelle
Eclache, Virginie
Lefebvre, Christine
Leblond, Véronique
Nguyen-Khac, Florence
Roos-Weil, Damien
author_sort Algrin, Caroline
collection PubMed
description
format Online
Article
Text
id pubmed-10230425
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-102304252023-06-01 Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study) Algrin, Caroline Pérol, Louis Chapiro, Elise Baseggio, Lucile Maloum, Karim Settegrana, Catherine Lesesve, Jean-François Siavellis, Justine Delmer, Alain Michallet, Anne-Sophie Ferrant, Emmanuelle Feugier, Pierre Tomowiak, Cécile Brion, Annie Ghez, David Fornecker, Luc-Matthieu Ivanoff, Sarah Struski, Stéphanie Sutton, Laurent Radford-Weiss, Isabelle Eclache, Virginie Lefebvre, Christine Leblond, Véronique Nguyen-Khac, Florence Roos-Weil, Damien Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-12-22 /pmc/articles/PMC10230425/ /pubmed/36546425 http://dx.doi.org/10.3324/haematol.2022.282162 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Letter to the Editor
Algrin, Caroline
Pérol, Louis
Chapiro, Elise
Baseggio, Lucile
Maloum, Karim
Settegrana, Catherine
Lesesve, Jean-François
Siavellis, Justine
Delmer, Alain
Michallet, Anne-Sophie
Ferrant, Emmanuelle
Feugier, Pierre
Tomowiak, Cécile
Brion, Annie
Ghez, David
Fornecker, Luc-Matthieu
Ivanoff, Sarah
Struski, Stéphanie
Sutton, Laurent
Radford-Weiss, Isabelle
Eclache, Virginie
Lefebvre, Christine
Leblond, Véronique
Nguyen-Khac, Florence
Roos-Weil, Damien
Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
title Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
title_full Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
title_fullStr Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
title_full_unstemmed Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
title_short Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
title_sort retrospective analysis of a cohort of 41 de novo b-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a filo study)
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230425/
https://www.ncbi.nlm.nih.gov/pubmed/36546425
http://dx.doi.org/10.3324/haematol.2022.282162
work_keys_str_mv AT algrincaroline retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT perollouis retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT chapiroelise retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT baseggiolucile retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT maloumkarim retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT settegranacatherine retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT lesesvejeanfrancois retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT siavellisjustine retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT delmeralain retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT michalletannesophie retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT ferrantemmanuelle retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT feugierpierre retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT tomowiakcecile retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT brionannie retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT ghezdavid retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT forneckerlucmatthieu retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT ivanoffsarah retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT struskistephanie retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT suttonlaurent retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT radfordweissisabelle retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT eclachevirginie retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT lefebvrechristine retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT leblondveronique retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT nguyenkhacflorence retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy
AT roosweildamien retrospectiveanalysisofacohortof41denovobcellprolymphocyticleukemiapatientsimpactofgeneticsandtargetedtherapiesafilostudy